Revance Therapeutics Inc (RVNC)

[marthambles]

This is from the latest 10K. Anyone have any idea how significant it is?

Interference, derivation, inter partes review, post-grant review or other proceedings brought at the USPTO may be necessary to determine the
priority or patentability of inventions with respect to our patents or patent applications or those of our licensors or collaborators, or those of our
competitors. For example, On July 1, 2021, we filed two petitions (IPR2021-01203 and IPR2021-01204) requesting inter partes review ("IPR") of Medy-
Tox, Inc. (“Medy-Tox”), U.S. patent 9,480,731, titled “Long Lasting Effect of New Botulinum Toxin Formulations.” On January 19, 2022, the USPTO
Trial and Appeal Board denied institution of the IPRs, and on February 18, 2022, we filed a motion for a rehearing of the decision. In 2013, Medy-Tox had
exclusively licensed its technology covered by this patent to Allergan plc which subsequently was acquired by AbbVie. On September 8, 2021, Medy-Tox
announced that its exclusive technology transfer agreement with AbbVie was terminated and rights for Medy-Tox’s technology covered by the patent
would be returned to Medy-Tox.